Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Patients With Germ Cell Tumors Undergoing 5 Day Cisplatin-based Chemotherapy: Hoosier Oncology Group Study QL12-153

NCT01736917 is registered in ClinicalTrials.gov with Lawrence Einhorn as lead sponsor.

NCT NCT01736917
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01736917 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Patients With Germ Cell Tumors Undergoing 5 Day Cisplatin-based Chemotherapy: Hoosier Oncology Group Study QL12-153
Lead sponsor
Lawrence Einhorn
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2013
Completion date
June 30, 2015
Enrollment
65 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapy-induced nausea and vomiting